Qizhen Shi, MD, PhD, and her laboratory have been awarded a number of grants that help them propel their lifesaving hemophilia A and hemophilia B research.
Recent grants include:
R01 HL102035, “Platelet-derived FVIII gene therapy of hemophilia A,” Role: PI (2010-2024)
R01 HL142791, “A phase I clinical trial testing feasibility of hematopoietic stem cell gene therapy using platelet FVIII to safely improve hemostasis for severe hemophilia A with inhibitory antibodies to FVIII,” Role: Co-I (2019-2024)
Joan Cox Gill CCBD/MSI Clinical & Translational Pilot Award, "Evaluating T follicular helper cells in FVIII inhibitor development and ITI in patients with Hemophilia A", Role: PI (2021-2023)”.
MACC FUND, “FVIII immune responses in hemophilia A,” Role: PI
In her laboratory, Qizhen Shi is supported by lab staff including a research technologist, postdoctoral fellow and animal technicians.
Publications
Qizhen Shi, MD, PhD, has been published in numerous scientific and medical journals for her research of hemophilia A and hemophilia B.
Qizhen Shi Laboratory
The Qizhen Shi, MD, PhD, laboratory at Versiti Blood Research Institute studies gene and cell therapies for treatment of hemophilia A and hemophilia B.
Qizhen Shi, MD, PhD
Dr. Shi is a senior investigator at Versiti Blood Research Institute who studies new treatments for patients with hemophilia.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking ACCEPT, you consent to the use of all the cookies.